Weitzman ECHO COVID-19: Clinical Presentations and Lessons Learned from the Front Lines
Download as PPTX, PDF0 likes574 views
This document provides information on a continuing medical education webinar about COVID-19. It includes objectives to update attendees on epidemiology, review any positive findings, and continue collaborative efforts to fight the virus. Statistics are presented on COVID-19 cases and hospitalizations increasing in the US and New York City. Some positive news includes Gilead allowing generic development of Remdesivir. Clinical presentations from the front lines revealed unexpected findings like renal, heart, and liver disease as well as hypercoagulable states and strokes. Rates are shown by borough, age, gender, and race/ethnicity in NYC. Milestones like social distancing policies were used to guide response. Clinical takeaways stressed this is a
Weitzman ECHO COVID-19: Clinical Presentations and Lessons Learned from the Front Lines
- 1. COVID-19 Clinical Presentations and Lessons Learned from the Front Lines May 13, 2020
- 2. CME Credit • Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians. The Bridgeport Hospital Yale New Haven Health designates this live activity for a maximum of one (1) AMA PRA Category 1 CreditsTM. Physicians should claim only credits commensurate with the extent of their participation in the various activities. • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Bridgeport Hospital Yale New Haven Health and the Weitzman Institute. Bridgeport Hospital Yale New Haven Health is accredited by the Connecticut State Medical Society to provide continuing medical education for physicians. • The content of this activity is not related to products or services of an ACCME- defined commercial interest; therefore, no one in control of content has a relevant financial relationship to disclose and there is no potential for conflicts of interest.
- 4. Objectives - Update on epidemiology (SARS-CoV-2, COVID-19) - Review any good news? - Continue team efforts to fight the virus
- 5. COVID-19 in the United States 1,367,491 cases on 5/12/20 – up from 1,203,673 cases last week (5/5/20) - https://coronavirus.jhu.edu/map.html
- 6. Any good news? • Remdesivir: –Gilead to allow wide-spread generic development • Continuing the fight: –10,000th COVID-19 discharge
- 8. Stay safe -- Stay up to date • https://www.cdc.gov/coronavirus/2019- ncov/index.html https://emergency.cdc.gov/coca/calls/2020/ • https://www.who.int/emergencies/disea ses/novel-coronavirus-2019 • https://covidactnow.org/ • https://coronavirus.jhu.edu/map.html
- 9. COVID-19: Clinical Presentations and Lessons Learned from the Front Lines Joseph Masci, MD Chairman of Global Health, Elmhurst Hospital Center Professor of Medicine, Infectious Disease & Emma Kaplan-Lewis, MD HIV Clinical Quality Director, NYC Health and Hospitals Assistant Professor of Medicine, Infectious Disease
- 10. Outline • Unexpected Findings • Demographics of COVID-19 in NYC • Indicators used to inform policy (ie. Social distancing) • Clinical takeaways
- 11. Unexpected Findings • Pulmonary disease • Renal disease • Heart disease • Liver disease • Hypercoagulable state • Strokes • Kawasaki-like syndrome • Changing strains of the virus
- 12. NYC COVID-19 Cases- as of 5/3
- 13. NYC COVID-19 Hospitalizations- as of 5/3
- 14. NYC COVID-19 Deaths- as of 5/4
- 15. Rates by Borough
- 16. Cases by Age and Gender
- 17. Hospitalizations and Deaths by Gender
- 18. Hospitalizations and Deaths by Race/Ethnicity
- 19. Milestones Used to Guide Social Distancing Policies
- 20. Clinical Takeaways • This is truly unlikely anything our modern day healthcare system has ever experienced • Approach embodies art > science of medicine • Many experimental treatments tried in absence of good evidence/guidance on who/when to treat – Hydroxychloroquine +/- Azithromycin – Remdesivir – Convalescent plasma – Tocilizumab/Sarilumab – Anticoagulation – Steroids • A collaborative healthcare system can work wonders to offload surge and save lives
- 21. 21